New research supports the use of human-derived positron emission tomography (PET) reporter gene imaging after chimeric antigen receptor (CAR) infusion, as a tool to monitor immune cells deployed by the therapy & how well they are working. Read more: ow.ly/YknA50SGngG

Considering its association with greater overall mortality, researchers recommend preventive strategies to protect high-risk patients against cytomegalovirus (CMV) reactivation following chimeric antigen receptor (CAR) T-cell therapy. Read more on Nucleus: ow.ly/f0j650SGnig

Clinical evidence does not support routine monitoring of #CARTcell therapy recipients for human herpesvirus-6B (HHV-6B) reactivation or disease, which occur at low rates in this patient population. Read more: ow.ly/eWCt50SGmGR

A recent study, published in@CellDiscovery, has demonstrated the efficacy and safety of a novel multifunctional M10 #CARTcells therapy in patients with HIV-1. Read more on Nucleus: ow.ly/x4HQ50SW6tM

Researchers have identified a non-functional variant of the P2X purinocepter 7 (npP2X7) receptor as a promising target for chimeric antigen receptor #CARTcells treatment in patients with ovarian cancer. Read more on Nucleus: ow.ly/v8VL50SW6xs Clinical & Translational Immunology

A recent study has identified the circadian rhythm of TILs as a key determinant in efficacy of immunotherapy treatments such as #CARTcells therapy & immune checkpoint blockade. Read more on Nucleus: ow.ly/QsKZ50SW6CG Cell

New research supports the use of human-derived positron emission tomography (PET) reporter gene imaging after chimeric antigen receptor (CAR) infusion, as a tool to monitor immune cells deployed by the therapy & how well they are working. Read more: ow.ly/YknA50SGngG

Investigators identified a novel approach that markedly enhances lentiviral transduction efficiency of primary human NK cells, which they paired with a novel in vitro expansion protocol. Read more on Nucleus: ow.ly/fxUt50SGncv

Considering its association with greater overall mortality, researchers recommend preventive strategies to protect high-risk patients against cytomegalovirus (CMV) reactivation following chimeric antigen receptor (CAR) T-cell therapy. Read more on Nucleus: ow.ly/f0j650SGnig

Our new infographic series turns the "Best of CAR T at the 2024 Tandem Meetings" webinar series from into digestible graphics for reading and sharing. View the new infographics on Nucleus: ow.ly/uxfO50T6EA1

Created with content from our Best of CAR T at #Tandem24 webinar series, this infographic features key insights on #CARTcells & late effects, including secondary malignancies. View the full series of infographics: ow.ly/wcGC50T6EHQ

Research with human samples and mouse models found chimeric antigen receptor #CARTcells aimed at glypican-2 (GPC2) could delay ocular loss in patients with metastatic retinoblastoma. Read more on Nucleus, ASTCT's content hub: ow.ly/KeEw50T6FLz

Considering its association with greater overall mortality, researchers recommend preventive strategies to protect high-risk patients against cytomegalovirus (CMV) reactivation following chimeric antigen receptor (CAR) T-cell therapy. Read more on Nucleus: ow.ly/f0j650SGnig

Created with content from our Best of CAR T at #Tandem24 webinar series, this infographic features key insights on the biology of relapse after transplant and cellular therapy. View the full series of infographics: ow.ly/wcGC50T6EHQ

Scientists suspect immune modulation with anti-CD3 monoclonal antibody (mAb) can unlock the potential of in-utero HCT, an experimental intervention to treat sickle cell and other disorders before a child is even born. Read more on Nucleus: ow.ly/Bq4t50T6GgM

Created with content from our Best of CAR T at #Tandem24 webinar series, this infographic features key tips for outpatient #CARTcell therapy. View the full series of infographics: ow.ly/wcGC50T6EHQ

Our new infographic series turns the "Best of CAR T at the 2024 Tandem Meetings" webinar series from into digestible graphics for reading and sharing. View the new infographics on Nucleus: ow.ly/uxfO50T6EA1

Starting this week, content which would usually be posted to this account, Nucleus Plus: CAR T, will now be posted from ASTCT. Be sure to follow ASTCT for all your CAR T-cell therapy content and updates.

ICYMI: Content which would usually be posted to this account, Nucleus Plus: CAR T, will now be posted from ASTCT. Be sure to follow ASTCT for all your CAR T-cell therapy content and updates!